GMP Certified / Mometasone Furoate Nasal Spray 50mcg

• Customization: Available
• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Model NO.: Nasal Spray
• Documentation: Copp, COA
• Factory Certification: GMP
• Transport Package: Carton
• Specification: 50mcg
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Product Description

Generic Name	Mometasone Furonate Nasal Spray
Strength	50 mcg
Packing	1 bottle/box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Mometasone Furonate Nasal Spray 50mcg

Character:
Mometasone furoate nasal spray is a quantitative hand press-type spray device with white to quasi-white suspension.

Indications:
This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children aged 3 to 11 years. For patients who have had moderate to severe symptoms of seasonal allergic rhinitis, it is recommended to use this product as a preventive treatment 2-4 weeks before the start of pollen season.

Matters needing attention:
Do not puncture the nozzle. Cleaning of nasal sprays: Regular cleaning of nasal sprays is very important, otherwise it will affect the normal work of nasal sprays. When cleaning, remove the dust cap, gently remove the nozzle, clean the nozzle and dust cap in warm water, and then rinse under the running water. Do not insert needles or other sharp instruments into the nozzle, this operation will damage the nozzle, resulting in the correct dose of medication cannot be released. After cleaning, this product can be placed in a warm space to dry, restore the nozzle to the bottle, and cover the dust-proof cap. When using for the first time after cleaning, hand press the spray twice to restart. This product should not be used for untreated local infections involving the mucous membranes of the nose. Because glucocorticoids inhibit wound healing, nasal glucocorticoids should not be used in patients who have recently undergone nasal surgery or suffered trauma before wound healing. After 12 months of treatment, no atrophy of the nasal mucosa was observed, and Mometasone furoate restored the nasal mucosa to normal histological manifestations. As with any drug in long-term use, the nasal mucosa should be examined regularly in patients who have been using this drug for several months or longer, and if a local fungal infection occurs in the nasopharynx, this drug should be discontinued or appropriate treatment should be given. Persistent nasopharyngeal irritation may be an indication of discontinuation of this drug. Use with caution in patients with active or resting respiratory tuberculosis infection, untreated fungal, bacterial, systemic viral infection, or ocular herpes simplex. No inhibition of the hypothalamic-pituitary-adrenal (HPA) axis was observed after long-term use of this product, but careful attention should be paid to patients who switched to this product after long-term use of systemic glucocorticoids. These patients may have renal gland insufficiency due to discontinuation of systemic glucocorticoids, and it takes several months for HPA axis function to recover. If these patients develop signs and symptoms of adrenal insufficiency, systemic glucocorticoids should be resumed, and other treatments and appropriate measures should be taken. In a placebo-controlled clinical trial, pediatric patients using the product 100μg daily for up to one year were found to slow growth and development. In some patients, systemic glucocorticoid withdrawal symptoms such as initial joint and/or muscle pain, fatigue, and depression may occur despite relief of nasal symptoms when systemic glucocorticoid is replaced with this product, and patients should be encouraged to continue treatment with this product. In addition, systemic hormone conversion to nasal local application can also expose pre-existing allergic diseases, such as allergic conjunctivitis and eczema, which are suppressed by systemic medication. Patients treated with glucocorticoids may have suppressed immune function, so they should be aware of the risk of certain infections (such as chickenpox, measles), and if this happens, it is important to get guidance from a doctor. Perforation of the nasal septum or increased intraocular pressure after inhalation of glucocorticoids by intranasal aerosol has been rarely reported.

Pharmacology and toxicology:
Mometasone furoate is a topical glucocorticoid that exerts local anti-inflammatory effects at doses that do not cause systemic effects.

Storage:
Store at 2ºC to 25ºC